MA35535B1 - Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes en tant qu'antagonistes de v1a - Google Patents
Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes en tant qu'antagonistes de v1aInfo
- Publication number
- MA35535B1 MA35535B1 MA36919A MA36919A MA35535B1 MA 35535 B1 MA35535 B1 MA 35535B1 MA 36919 A MA36919 A MA 36919A MA 36919 A MA36919 A MA 36919A MA 35535 B1 MA35535 B1 MA 35535B1
- Authority
- MA
- Morocco
- Prior art keywords
- azulenes
- triaza
- oxa
- benzo
- antagonists
- Prior art date
Links
- YGKVYZJHZKYBLL-UHFFFAOYSA-N 1,6-dihydro-[1,2,4]triazolo[4,3-a][4,1]benzoxazepine Chemical class O1CC2=CC=CC=C2N2CN=NC2=C1 YGKVYZJHZKYBLL-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- RKTMZBLOIVSOBT-UHFFFAOYSA-N 4,6-dihydro-[1,2,4]triazolo[4,3-a][4,1]benzoxazepine Chemical class C1OCC2=CC=CC=C2N2C=NN=C12 RKTMZBLOIVSOBT-UHFFFAOYSA-N 0.000 abstract 1
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
- 102000002852 Vasopressins Human genes 0.000 abstract 1
- 108010004977 Vasopressins Proteins 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000012761 aggressive behavior Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- -1 their manufacture Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 229960003726 vasopressin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes, qui agissent en tant que modulateurs du récepteur v1a, et en particulier en tant qu'antagonistes du récepteur v1a, leur fabrication, des compositions pharmaceutiques contenant ceux-ci et leur utilisation en tant que médicaments. Les composés actifs de la présente invention sont utiles en tant qu'agents thérapeutiques à action périphérique et centrale dans les affections suivantes : la dysménorrhée, un trouble sexuel masculin ou féminin, l'hypertension, l'insuffisance cardiaque chronique, une sécrétion inappropriée de vasopressine, la cirrhose du foie, le syndrome néphrotique, l'anxiété, des troubles dépressifs, un trouble obsessionnel compulsif, des troubles du spectre de l'autisme, la schizophrénie, et un comportement agressif.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11182796 | 2011-09-26 | ||
| PCT/EP2012/068721 WO2013045373A1 (fr) | 2011-09-26 | 2012-09-24 | Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes en tant qu'antagonistes de v1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35535B1 true MA35535B1 (fr) | 2014-10-02 |
Family
ID=46881068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36919A MA35535B1 (fr) | 2011-09-26 | 2014-04-15 | Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes en tant qu'antagonistes de v1a |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8828989B2 (fr) |
| EP (1) | EP2760871B1 (fr) |
| JP (1) | JP5909554B2 (fr) |
| KR (1) | KR101682777B1 (fr) |
| CN (1) | CN103827121B (fr) |
| AR (1) | AR087999A1 (fr) |
| AU (1) | AU2012314593B2 (fr) |
| BR (1) | BR112014006945A2 (fr) |
| CA (1) | CA2844581A1 (fr) |
| CL (1) | CL2014000717A1 (fr) |
| CO (1) | CO6870036A2 (fr) |
| CR (1) | CR20140092A (fr) |
| EA (1) | EA024990B1 (fr) |
| EC (1) | ECSP14013271A (fr) |
| IN (1) | IN2014CN02169A (fr) |
| MA (1) | MA35535B1 (fr) |
| MX (1) | MX2014003643A (fr) |
| PE (1) | PE20141397A1 (fr) |
| PH (1) | PH12014500582A1 (fr) |
| SG (1) | SG2014010607A (fr) |
| TW (1) | TWI553013B (fr) |
| UA (1) | UA111623C2 (fr) |
| WO (1) | WO2013045373A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4185570B1 (fr) * | 2020-07-23 | 2024-10-09 | F. Hoffmann-La Roche AG | Triazoles substitués par cyclohexyle utilisés en tant qu'antagonistes du récepteur v1 de la vasopressine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1147115E (pt) | 1999-01-19 | 2004-02-27 | Ortho Mcneil Pharm Inc | Benzodiazepinas triciclicas como antagonistas do receptor da vasopressina |
| US6765004B1 (en) | 1999-06-17 | 2004-07-20 | Ortho-Mcneil Pharmaceutical, Inc. | Indoloazepines as vasopressin receptor antagonists |
| US7119088B2 (en) | 2003-02-19 | 2006-10-10 | Pfizer Inc. | Triazole compounds useful in therapy |
| GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| MX2007002248A (es) * | 2004-08-25 | 2008-10-02 | Pfizer | Triazolobenzodiazepinas y su uso como antagonistas de vasopresina. |
| PE20110590A1 (es) * | 2008-11-18 | 2011-08-31 | Hoffmann La Roche | Alquilciclohexileteres de dihidrotetraazabenzoazulenos |
| MY150837A (en) * | 2008-11-28 | 2014-02-28 | Hoffmann La Roche | Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists |
-
2012
- 2012-08-23 US US13/592,493 patent/US8828989B2/en active Active
- 2012-09-24 KR KR1020147010783A patent/KR101682777B1/ko not_active Expired - Fee Related
- 2012-09-24 MX MX2014003643A patent/MX2014003643A/es unknown
- 2012-09-24 BR BR112014006945A patent/BR112014006945A2/pt not_active IP Right Cessation
- 2012-09-24 CA CA2844581A patent/CA2844581A1/fr not_active Abandoned
- 2012-09-24 CN CN201280046689.0A patent/CN103827121B/zh not_active Expired - Fee Related
- 2012-09-24 JP JP2014532331A patent/JP5909554B2/ja not_active Expired - Fee Related
- 2012-09-24 UA UAA201403611A patent/UA111623C2/uk unknown
- 2012-09-24 EA EA201490558A patent/EA024990B1/ru not_active IP Right Cessation
- 2012-09-24 WO PCT/EP2012/068721 patent/WO2013045373A1/fr not_active Ceased
- 2012-09-24 IN IN2169CHN2014 patent/IN2014CN02169A/en unknown
- 2012-09-24 AU AU2012314593A patent/AU2012314593B2/en not_active Ceased
- 2012-09-24 PE PE2014000394A patent/PE20141397A1/es not_active Application Discontinuation
- 2012-09-24 SG SG2014010607A patent/SG2014010607A/en unknown
- 2012-09-24 PH PH1/2014/500582A patent/PH12014500582A1/en unknown
- 2012-09-24 EP EP12761740.5A patent/EP2760871B1/fr active Active
- 2012-09-25 TW TW101135168A patent/TWI553013B/zh not_active IP Right Cessation
- 2012-09-25 AR ARP120103514A patent/AR087999A1/es unknown
-
2014
- 2014-01-31 CO CO14020668A patent/CO6870036A2/es not_active Application Discontinuation
- 2014-02-26 CR CR20140092A patent/CR20140092A/es unknown
- 2014-03-24 CL CL2014000717A patent/CL2014000717A1/es unknown
- 2014-03-26 EC ECSP14013271 patent/ECSP14013271A/es unknown
- 2014-04-15 MA MA36919A patent/MA35535B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201490558A1 (ru) | 2014-06-30 |
| CL2014000717A1 (es) | 2014-10-03 |
| CR20140092A (es) | 2014-03-20 |
| EA024990B1 (ru) | 2016-11-30 |
| IN2014CN02169A (fr) | 2015-05-29 |
| AR087999A1 (es) | 2014-04-30 |
| ECSP14013271A (es) | 2014-05-31 |
| CA2844581A1 (fr) | 2013-04-04 |
| CN103827121A (zh) | 2014-05-28 |
| AU2012314593B2 (en) | 2016-09-29 |
| TW201315737A (zh) | 2013-04-16 |
| US20130079333A1 (en) | 2013-03-28 |
| WO2013045373A1 (fr) | 2013-04-04 |
| JP5909554B2 (ja) | 2016-04-26 |
| KR101682777B1 (ko) | 2016-12-05 |
| AU2012314593A1 (en) | 2014-02-20 |
| EP2760871A1 (fr) | 2014-08-06 |
| MX2014003643A (es) | 2014-04-30 |
| CO6870036A2 (es) | 2014-02-20 |
| AU2012314593A8 (en) | 2014-03-27 |
| UA111623C2 (uk) | 2016-05-25 |
| KR20140079790A (ko) | 2014-06-27 |
| EP2760871B1 (fr) | 2018-07-18 |
| US8828989B2 (en) | 2014-09-09 |
| TWI553013B (zh) | 2016-10-11 |
| PH12014500582A1 (en) | 2014-04-28 |
| PE20141397A1 (es) | 2014-10-13 |
| CN103827121B (zh) | 2016-08-03 |
| SG2014010607A (en) | 2014-05-29 |
| NZ620653A (en) | 2016-03-31 |
| JP2014527993A (ja) | 2014-10-23 |
| BR112014006945A2 (pt) | 2017-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34252B1 (fr) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | |
| MA34174B1 (fr) | Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a | |
| MA32781B1 (fr) | Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine | |
| MA34173B1 (fr) | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes | |
| CR10577A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| MA35246B1 (fr) | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 | |
| MA35191B1 (fr) | Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2 | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
| BR112012024306A2 (pt) | aril-cicloexil-tetraazabenzo[e] azulenos | |
| MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA37990B1 (fr) | Benzamides | |
| MX2014003600A (es) | Ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas v1a. | |
| MA35535B1 (fr) | Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulènes en tant qu'antagonistes de v1a | |
| MA39139B1 (fr) | Spiro-oxazolones | |
| MA46464B1 (fr) | Polymorphes de l'agoniste de récepteur muscarinique | |
| TH126653A (th) | เฮเทอโรไบเอริล-ไซโคลเฮกซิล-เตตระอะซาเบนโซ[e]อะซูลีน | |
| MA35894B1 (fr) | Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k | |
| TH127475A (th) | เฮเทอโรอะริล-ไซโคลเฮกซิล-เตตระอะซาเบนโซ[e]อะซูลีน (Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes) | |
| MA34201B1 (fr) | Carboxamides d'imidazole fusionnes utilises en tant que modulateurs du trpv3 |